Figure 2.
TBC1D8 is amplified and up-regulated in the more aggressive OVCA cells and OVCA tissues, and high TBC1D8 level is significantly associated with a poor prognosis for OVCA patients. (A) SILAC quantitative proteomics analysis identified that TBC1D8 expression is markedly up-regulated in the more aggressive OVCA cells OVCAR-3high compared with the OVCAR-3 cells. (B) The TBC1D8 mRNA and protein levels of the more aggressive OVCA cells and their parental cells were determined. (C, D) The TBC1D8 mRNA (C) and protein (D) levels between OVCA tissues and normal ovarian tissues were determined. (E) The TBC1D8 protein levels in 141 OVCA tissues were detected by IHC assay. Representative IHC images of TBC1D8 level in OVCA tissues. (F) Differences in TBC1D8 score in OVCA with clinical stage I, II, III and IV are presented as a box plot. (G) Differences in TBC1D8 score in OVCA samples between metastasis and nonmetastasis are presented as a box plot. (H) TBC1D8 gene copy number was analyzed in OVCA tissues, whole blood and normal ovarian tissues in the TCGA ovarian dataset. (I, J) Associations between TBC1D8 levels and the percentage of tumor recurrence (I) and patient death (J) were analyzed in 141 OVCA samples. (K, L) Kaplan-Meier plots for the overall patient survival rate (K) and the tumor-free survival rate (L) of patients with OVCA in TBC1D8 low and TBC1D8 high groups. Score of 0-3 was indicative of low TBC1D8 level (low) and scores of 4-7 were indicative of high TBC1D8 level (high) in OVCA tissues.